Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 9,067 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total value of $275,092.78. Following the completion of the transaction, the chief financial officer owned 91,617 shares of the company’s stock, valued at $2,779,659.78. The trade was a 9.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, January 5th, Oluyemi Okupe sold 9,070 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.79, for a total transaction of $306,475.30.
• On Monday, December 22nd, Oluyemi Okupe sold 23,090 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.81, for a total transaction of $853,513.47.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47.

Hims & Hers Health Price Performance

Shares of HIMS opened at $28.83 on Thursday. The firm has a market capitalization of $6.56 billion, a price-to-earnings ratio of 53.39, a PEG ratio of 5.16 and a beta of 2.37. The firm’s fifty day simple moving average is $35.20 and its 200-day simple moving average is $45.31. Hims & Hers Health, Inc. has a twelve month low of $23.97 and a twelve month high of $72.98. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). The business had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. During the same period last year, the company earned $0.32 EPS. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has authorized a stock repurchase program on Monday, November 17th that allows the company to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of HIMS. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth about $26,000. Quent Capital LLC purchased a new position in shares of Hims & Hers Health during the third quarter worth about $28,000. Flagship Harbor Advisors LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at about $28,000. Binnacle Investments Inc purchased a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $28,000. Finally, Quaker Wealth Management LLC acquired a new stake in Hims & Hers Health during the 2nd quarter worth approximately $29,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on HIMS. BTIG Research reiterated a “buy” rating and issued a $85.00 price target on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research report on Monday, January 5th. Bank of America boosted their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. Finally, Zacks Research cut Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $44.54.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.